Health
FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients – FDA.gov
FDA has authorized marketing of a new device intended for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis
For Immediate Release:
March 26, 2021
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that…
-
General21 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
General7 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News22 hours agoWorker rushed to hospital after becoming trapped in machinery during horror workplace accident in Salisbury
-
General19 hours agoRobin Williams’s daughter begs fans to stop making AI content of her father